AMED Form 25 Notifies Withdrawal of Securities from Nasdaq

Rhea-AI Filing Summary

Amedisys Inc (AMED) submitted a Form 25 notification indicating the removal/withdrawal of a class of its securities from listing and/or registration on the Nasdaq Stock Market LLC. The filing lists the issuer name, Nasdaq as the exchange, and the issuer's Baton Rouge address and phone number. The form states the Exchange and the Issuer have complied with the applicable rules governing withdrawal, but the specific rule box selected and any signature or date details are not present in the provided text.

Positive

• Exchange and issuer assert compliance with the applicable rules (17 CFR 240.12d2-2(b) and 17 CFR 240.12d-2(c)) for withdrawal from listing/registration

Negative

• A class of Amedisys securities is being removed/withdrawn from listing and/or registration on Nasdaq, which is a material change for shareholders
• Key details are missing: the specific class of securities affected, the selected rule checkbox, execution signature, and effective date are not provided in the supplied text

Insights

Securities Listing Specialist

TL;DR: Form 25 notifies that AMED's securities are being removed from Nasdaq and both the Exchange and issuer assert regulatory compliance.

The filing is procedural: it identifies Amedisys Inc and Nasdaq and states compliance with 17 CFR 240.12d2-2(b) and 17 CFR 240.12d-2(c) regarding withdrawal from listing/registration. The document lacks the executed signature/date fields and does not specify which exact class of securities is affected or whether the removal is voluntary or delisting by Nasdaq, beyond the generic compliance statements. For investors, the material fact present is the removal/withdrawal action; all other material details are absent from the text provided.

Corporate Governance Analyst

TL;DR: The filing signals a change in trading venue/registration status for AMED shares while showing procedural compliance statements.

The Form 25 content is limited but clear that Nasdaq certifies it has grounds for filing and that both Exchange and issuer complied with the referenced regulatory provisions for removal/withdrawal. The absence of the chosen rule checkbox, signature, date, and the specific class description prevents assessment of timing, investor options (e.g., continued OTC trading), or corporate rationale. The disclosure is material but incomplete as presented.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

000-24260

Issuer:	AMEDISYS INC
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	3854 American Way, Suite A
	Baton Rouge	LOUISIANA	70816
Telephone number:					1 225 292-2031

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-08-14	By	Tara Petta		AVP
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 25 filing for Amedisys (AMED) indicate?

The filing notifies the removal/withdrawal of a class of Amedisys securities from Nasdaq and states that the Exchange and issuer complied with the referenced withdrawal rules.

Which Nasdaq rule provisions are referenced in the AMED Form 25?

The document references 17 CFR 240.12d2-2(b) and 17 CFR 240.12d-2(c) as governing the withdrawal and states compliance with those provisions.

Does the provided filing identify which class of AMED securities is removed?

No. The supplied text does not specify the description of the class of securities affected.

Is there an effective date or signature on the provided Form 25 for AMED?

No. The provided excerpt does not include a signed name, title, or date; those fields are blank in the text supplied.

Where is Amedisys' principal office listed in the filing?

The filing lists Amedisys' address as 3854 American Way, Suite A, Baton Rouge, Louisiana 70816 and a telephone number of 1 225 292-2031.